Lacosamid Stada

Lacosamide, the active ingredient in Lacosamid Stada, is an anticonvulsant presented as a tablet for oral use. It treats partial-onset seizures in patients with focal epilepsy.

GNH USA supplies Lacosamid Stada as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is used in the management of focal epilepsy and related seizure disorders.

Partial-onset seizures: reduces seizure frequency as monotherapy or add‑on therapy. Adjunctive therapy in epilepsy: combined with other antiepileptic drugs to improve seizure control. Focal epilepsy: helps control seizures originating from a specific brain region.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue - Blurred vision - Coordination problems

Serious or Rare Side Effects: - Cardiac arrhythmias (e.g., PR interval prolongation) - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior - Liver enzyme elevations - Hypersensitivity reactions (e.g., anaphylaxis)

When prescribing Lacosamide, consider the following precautions to ensure safe use. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver function and consider dose modification. - Cardiac conduction disorders: avoid in patients with known PR interval prolongation. - Pregnancy: risk unknown, use only if benefits outweigh risks. - Concomitant sodium channel blockers: monitor for additive effects on cardiac conduction. - Store at room temperature: keep in original packaging, protect from moisture and light.

Lacosamide can interact with other medicines; notable interactions include:

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): may cause severe cardiac conduction disturbances. - Other sodium channel blockers (e.g., carbamazepine, phenytoin): increase risk of arrhythmias. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise lacosamide plasma levels.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): may modestly increase levels. - CYP2C19 inducers (e.g., rifampin): may reduce efficacy. - Concomitant use with other antiepileptics (e.g., valproate): monitor seizure control and side effects.